Chemotherapy is one of most common cancer treatments in clinics. In most cases, the clinical responses show that the efficacy of chemotherapy is limited by the development of multidrug resistance (MDR) in cancer cells during a long period of treatment. To overcome the resistance, higher doses of toxic anticancer drugs are sometimes required, which can also kill healthy cells and result in adverse side effects on healthy organs. Thus, the development of an effective strategy to overcome the multidrug resistance in chemotherapy remains a major challenge in the treatment of cancers. This project aims to develop synergic co-delivery system to enhance cancer treatment efficiency and understand the combinational pathway.

  Are you interested in a PhD at the AIBN? Click here, and start your journey today. 



chemotherapy, cancer, multidrug resistance, mdr, xu group

Supervisor name

Professor Zhi Ping (Gordon) Xu
Senior Group Leader
Xu Group

Supervisor email